Harvest Fund Management Trims Eli Lilly Stake

Hedge fund reduces position in pharmaceutical giant by over 37%

Mar. 14, 2026 at 8:37am

Got story updates? Submit your updates here. ›

Harvest Fund Management Co. Ltd., a Chinese investment management firm, has reduced its stake in Eli Lilly and Company (NYSE: LLY) by 37.2% during the third quarter. The firm now owns 7,535 shares of the pharmaceutical company's stock, down from 11,992 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative drugs and therapies. Institutional investors closely monitor changes in ownership of major pharmaceutical stocks as they can signal shifts in market sentiment or changes in a company's outlook.

The details

According to a recent SEC filing, Harvest Fund Management sold 4,467 shares of Eli Lilly stock during the third quarter. The firm's total position in Eli Lilly is now valued at $5.74 million. Harvest Fund Management is a China-based asset management firm that invests in a variety of sectors, including healthcare and pharmaceuticals.

  • Harvest Fund Management reduced its Eli Lilly stake during the third quarter of 2026.

The players

Harvest Fund Management Co. Ltd.

A Chinese investment management firm that has reduced its position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company known for its innovative drugs and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Harvest Fund Management's Eli Lilly stake, while relatively small, could signal a shift in sentiment around the pharmaceutical company's outlook. Investors will likely continue to monitor changes in institutional ownership of Eli Lilly stock for clues about the company's future performance.